Triple-negative breast cancer

Syncell Expands Into the United States With a New Office in Watertown, MA

Retrieved on: 
Montag, Dezember 25, 2023
Research, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Laboratory, Protein, ALS, Proteomics, Alzheimer's disease, Triple-negative breast cancer, GRASP

Syncell, a life science technology company known for pioneering next-generation spatial proteomics, is pleased to announce the inauguration of its US main office in Watertown, Massachusetts.

Key Points: 
  • Syncell, a life science technology company known for pioneering next-generation spatial proteomics, is pleased to announce the inauguration of its US main office in Watertown, Massachusetts.
  • This expansion echoes the demands from the U.S. customers who are highly interested in Syncell’s Microscoop technology.
  • "Since Syncell's inception in 2020 in Taiwan, we have thought to make our unique microscopic scooping technology globally available.
  • This office will also serve as a base for Syncell’s scientific and technical support teams in the U.S.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231221684718/en/

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Mittwoch, November 15, 2023
CNS, Sale, CSMC, Retina, Patient, Triple-negative breast cancer, Attention deficit hyperactivity disorder, Cayman, Investigational New Drug, US FDA, Licensed production, Cancer, Power purchase agreement, SIV, Security (finance), Toxicity, Plasma protein binding, Syndrome, IND, Surgeon, TGA, BioLite, ADHD, Taiwan Stock Exchange, Sales management, Hydrogel, MDD, Pancreatic cancer, Depression, GMP, Good manufacturing practice, Bank statement, UCSF, MDS, University, Partnership, Phase, Drug development, Research, ANDA, Warrant, FDA, Dietary supplement, West Pharmaceutical Services, Share (finance), Pharmaceutical industry, Cryptocurrency, Qiu Zhonghui

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Dienstag, November 14, 2023
Senior, Entrepreneurship, CRS, Peptide, Regenerative Medicine Advanced Therapy, Patient, Triple-negative breast cancer, Cell, Research, Pharmacology, Therapy, Conference, ORR, Neurotoxicity, Infrared spectroscopy correlation table, Cytokine release syndrome, Uveal melanoma, Bristol Myers Squibb, Safety, Head, Cancer, Administration, CD4, PRAME, Uterine cancer, Lung cancer, Melanoma, Ovarian cancer, Half-life, Development, SAB, BRAF, CD8, MAGEA4, Cytopenia, TCR, Protein, FDA, DLT, Messenger, Cmax, Toxic epidermal necrolysis, Sarcoma, CMC, Neoplasm, Vaccine, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, Drug, Moderna, NSCLC

“Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.

Key Points: 
  • “Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • On September 11, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Montag, November 13, 2023
Breast, Woman, Health Canada, Research, Therapy, Conduct, Clinical trial, Comparison, Breast cancer, Administration, Patient, Triple-negative breast cancer, G&A, Ductal carcinoma, Neoplasm, Atossa, Seminal vesicles, Partnership, R, Research and development, Estrogen receptor, TNBC, Pharmaceutical industry, Fine chemical, Birth control, DCIS

Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS

Key Points: 
  • Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS
    SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended September 30, 2023, and provides an update on recent company developments.
  • Key developments from Q3 2023 and year to date include:
    80% Enrollment in Ongoing Phase 2 Karisma-Endoxifen Clinical Trial – the study is investigating (Z)-endoxifen in premenopausal women with measurable breast density.
  • Participants receive daily doses of (Z)-endoxifen for six months, over the course of which mammograms are conducted to measure reduction in breast density.
  • Full enrollment is expected by the end of 2023 and data is expected in the second half of 2024.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, November 9, 2023
Tumor-associated macrophage, Research, Annual general meeting, Renal cell carcinoma, Hereditary diffuse gastric cancer, Head, Colorectal cancer, ESMO, Administration, Patient, Triple-negative breast cancer, ASCO, MSK, FDA, Lung cancer, G&A, Immunotherapy, Patent, ORR, Ovarian cancer, MPH, Cancer, Trial of the century, Diagnosis, Nivolumab, SITC, Operation, Antibody, Research and development, R, Congress, Orphan, Society, TNBC, ISAC, NSCLC, Pharmaceutical industry, Vaccine, Cryptocurrency

Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.

Key Points: 
  • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.
  • Research and Development (R&D) Expenses – R&D expenses were $15.0 million for the quarter ended September 30, 2023, compared to $19.0 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.8 million for the quarter ended September 30, 2023, compared to $5.5 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.2 million for the quarter ended September 30, 2023, compared to $22.3 million for the same quarter in 2022.

Two Leading Breast Cancer Organizations Join Forces to Save Lives Through Early Detection

Retrieved on: 
Donnerstag, Dezember 7, 2023
Oncology, Health, Consumer, African American, Women, Teens, Seniors, Woman, Research, Radiation, Organization, Entrepreneurship, Love, BEA, Ageing, Triple-negative breast cancer, Disease, Mortality, Breast cancer, Multimedia, Statistics, Partnership, Work, News, Parity, TNBC, Birth control, Black, TOUCH

TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) is teaming up with the Bexa Equity Alliance (BEA) in a strategic partnership to change the game on breast cancer early detection for young Black women.

Key Points: 
  • TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) is teaming up with the Bexa Equity Alliance (BEA) in a strategic partnership to change the game on breast cancer early detection for young Black women.
  • Unlike traditional breast exams, the Bexa Breast Exam is a quick, accurate, painless exam that does not involve radiation and provides women with immediate results.
  • Currently, Black women aged 40-49 are 80% more likely to die of breast cancer than white women.
  • Triple-negative breast cancer (TNBC), the most aggressive breast cancer sub-type, is more common in young women .

Northwell Receives Largest Single Gift in Its History From Victoria and Lloyd Goldman to Support Expansion in Manhattan

Retrieved on: 
Mittwoch, November 15, 2023
Commercial Building & Real Estate, Construction & Property, Hospitals, Cardiology, Philanthropy, Practice Management, Managed Care, Health, Other Philanthropy, Constellation, Lloyd Goldman, Woman, Research, Metropolitan, Surgical oncology, DSM-IV codes, Radiation, Teaching hospital, Metropolitan Museum of Art, Lenox Health Greenwich Village, Multimedia, Oncology, Triple-negative breast cancer, Pharmacy, Heart, North Shore University Hospital, Third Avenue, Endometrial cancer, Weekend Update, Medical research, Lenox Hill Hospital, Hospital, Cancer, Imaging, Impossible, Medical imaging, Pharmaceutical industry, Management, New Yorker, Northwell Health, Art

In gratitude for a significant gift from Victoria and Lloyd Goldman — the largest single gift in Northwell’s history — Northwell Health will name its new medical pavilion under construction on the Upper East Side of Manhattan the Victoria and Lloyd Goldman Medical Pavilion.

Key Points: 
  • In gratitude for a significant gift from Victoria and Lloyd Goldman — the largest single gift in Northwell’s history — Northwell Health will name its new medical pavilion under construction on the Upper East Side of Manhattan the Victoria and Lloyd Goldman Medical Pavilion.
  • The gift was announced at Northwell’s annual Constellation Gala held at the Metropolitan Museum of Art on November 14th and includes an endowment to establish the Victoria and Lloyd Goldman Professorship.
  • View the full release here: https://www.businesswire.com/news/home/20231115848930/en/
    L-r: Northwell President and CEO Michael J. Dowling and benefactors Lloyd and Victoria Goldman stand beside a model of the future Victoria and Lloyd Goldman Medical Pavilion, which is slated to open on the Upper East Side of Manhattan in 2026.
  • The undisclosed gift amount contributes toward the $450 million, 15-floor, 200,000-square-foot complex, which is slated to open in 2026.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Retrieved on: 
Dienstag, November 14, 2023
Biotechnology, FDA, Medical Devices, Health, Oncology, MSD, HNSCC, PD-L1, Trastuzumab, NYSE, Cervical cancer, Head, Incidence, Patient, Triple-negative breast cancer, Agilent Technologies, Stomach cancer, Stomach, Pembrolizumab, Lung cancer, PD-1, Adenocarcinoma, Partnership, ESCC, Cancer, Merck & Co., Physician, CPS, GEJ, TNBC, NSCLC, Pharmaceutical industry, Vaccine, Merck

Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
  • PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic that can identify gastric or GEJ adenocarcinoma patients suitable for treatment with KEYTRUDA in combination with chemotherapy and trastuzumab plus fluoropyrimidine.
  • This marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval.
  • PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck (known as MSD outside the United States and Canada) as a companion diagnostic for KEYTRUDA.

MEDSIR presents promising results at SABCS 2023: ATRACTIB and DEBBRAH trials hold potential to improve the lives of advanced breast cancer patients

Retrieved on: 
Freitag, Dezember 8, 2023
Paclitaxel, Peripheral neuropathy, PD-L1, Brain, Research, Safety, SAN, Toxicity, Progression-free survival, Cohort, Bevacizumab, Hospital, Breast cancer, Fatigue, Patient, Triple-negative breast cancer, Trastuzumab deruxtecan, Neutropenia, HER2, Survival, Death, Cancer, Immunotherapy, Knowledge, HIV disease progression rates, TNBC, Medical imaging, Pharmaceutical industry

The results from the ATRACTIB trial, focusing on advanced triple-negative breast cancer (TNBC), and DEBBRAH Cohort 5, centered on HER2[+] or HER2-Low advanced breast cancer with leptomeningeal carcinomatosis, offer new hope for patients with limited treatment alternatives.

Key Points: 
  • The results from the ATRACTIB trial, focusing on advanced triple-negative breast cancer (TNBC), and DEBBRAH Cohort 5, centered on HER2[+] or HER2-Low advanced breast cancer with leptomeningeal carcinomatosis, offer new hope for patients with limited treatment alternatives.
  • This phase II clinical trial highlights the success of a combined therapy approach as a first-line treatment for advanced TNBC patients.
  • The DEBBRAH trial, focusing on HER2[+] or HER2-Low advanced breast cancer patients with brain metastases and/or leptomeningeal carcinomatosis, showcased promising results from Cohort 5, which specifically included patients with pathologically confirmed leptomeningeal carcinomatosis.
  • This rare but serious complication occurs in approximately 10% of advanced breast cancer patients and is associated with poor outcomes and limited therapeutic options.

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Research at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Montag, Dezember 4, 2023
PD-L1, Senior, Patient, Triple-negative breast cancer, Neoplasm, Prognosis, MBA, Cancer, Diagnosis, Doctor of Philosophy, Overalls, Clinical professor, Malignancy, NGS, Female, AI, Pregnancy, RNA, ID, BCL2, Brown University, Breast, FACP, Immunology, Breast cancer, Clonal hematopoiesis, Dana–Farber Cancer Institute, NTRK1, Disease, Phyllodes tumor, HER2, TNBC, Targeted therapy, Research, MPT, China Tribunal, NCI, Medicine, Genomics, POA, MD, Survival, Mayo Clinic, Concurrency, Biology, Dentistry, Pharmaceutical industry, Birth control, Medical imaging, Vaccine, Male, Caris

IRVING, Texas, Dec. 4, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enables novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan, and response to treatment. SABCS is being held December 5-9, 2023 (Booth #1433) in San Antonio, Texas.

Key Points: 
  • "The San Antonio Breast Cancer Symposium continues to be the premiere conference for breast cancer research," said George W. Sledge, Jr. , MD, Executive Vice President and Chief Medical Officer of Caris.
  • "As part of our continuing commitment to the breast cancer community, Caris is proud to share important clinical/translational research created with our academic partners on important breast cancer questions."
  • The results of this analysis indicate that male breast cancer has differential molecular and immune features compared to female breast cancer.
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.